

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

Novel dimeric alkaloids from the roots of *Thalictrum atriplex*

G. -Y. Gao; S. -B. Chen; S. -L. Chen; L. -W. Wang; P. -G. Xiao

To cite this Article Gao, G. -Y. , Chen, S. -B. , Chen, S. -L. , Wang, L. -W. and Xiao, P. -G.(2005) 'Novel dimeric alkaloids from the roots of *Thalictrum atriplex*', Journal of Asian Natural Products Research, 7: 6, 805 — 809

To link to this Article: DOI: 10.1080/1028602042000204117

URL: <http://dx.doi.org/10.1080/1028602042000204117>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Novel dimeric alkaloids from the roots of *Thalictrum atriplex*

G.-Y. GAO†, S.-B. CHEN†‡*, S.-L. CHEN†‡, L.-W. WANG† and P.-G. XIAO†

†Institute of Medicinal Plant Development, Peking Union Medical College, Chinese Academy of Medical Sciences, 100094, Beijing, China

‡Department of Applied Biology & Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong

(Received 18 September 2003; revised 29 October 2003; in final form 8 November 2003)

Two new bisbenzylisoquinoline alkaloids, neothalfine (**1**) and thaliatrine (**2**), together with three known dimeric alkaloids, thalifaberine, thalistine, and thalirecebine, have been isolated from the roots of *Thalictrum atriplex* Finet et Gagnep. Their structures have been established by spectroscopy. Compound **1** showed *in vitro* antiplatelet aggregation activities.

Keywords: *Thalictrum atriplex*; Bisbenzylisoquinoline alkaloids; Neothalfine; Thaliatrine

1. Introduction

Previous studies on the chemical constituents have indicated that plants of the genus *Thalictrum* (Ranunculaceae) are a rich resource of dimeric alkaloids, most of which possess many kinds of biological activities [1,2]. *Thalictrum atriplex* Finet et Gagnep. has been used as a Chinese and Tibetan folk medicine, distributed mainly in the southwest of China. Its roots have been used to treat infectious hepatitis, carbuncles, dysenteric diarrhea, and certain gastroenteric disorders [3]. No dimeric alkaloids from this species, or their biological activity, have been reported in the literature. In our research on this species, two new dimeric alkaloids, neothalfine (**1**) and thaliatrine (**2**) (figure 1), together with three known dimeric alkaloids have been isolated from the roots. Compound **1** contains two ether linkages connecting a benzylisoquinoline unit with a dehydroxyisoquinoline, a rare class of dimeric alkaloids. Compound **2** is a bisbenzylisoquinoline dimer, linked through one diphenyl ether. A biological assay indicates that **1** has potential antiplatelet aggregation activity.

2. Results and discussion

Neothalfine (**1**) was obtained as a white amorphous solid. The HR-FABMS of **1** shows the molecular ion peak at m/z 648, corresponding to the formula $C_{38}H_{36}O_8N_2$. The UV spectrum of **1** shows absorption maxima at 240, 256, 346 nm, indicating the presence

*Corresponding author. Tel.: +86-755-26737179. Fax: +86-755-26972852. E-mail: chensibao@hotmail.com




Figure 1. Structures of compounds **1** and **2**.

of a benzyloisoquinoline moiety. From EIMS data, the base peak at m/z 648, corresponding to the molecular ion, indicates that **1** is a dimeric alkaloid with two diphenyl ether groups [4]. The ^1H NMR spectrum of **1** (table 1) reveals one *N*-methyl, four *O*-methyl, one methylenedioxy, and ten aromatic protons. In the aliphatic region, from δ 2.38 to 3.12 (H-3, 4), only four protons are observed. The lack of four additional aliphatic protons of benzyloisoquinoline reveals that **1** has a dehydro-benzyloisoquinoline component. This hypothesis is supported by the two aromatic doublets of H-4' (δ 7.45, $J = 5.8$ Hz) and H-3' (δ 8.45, $J = 5.8$ Hz) and the low-field signals of H-9' (δ 4.57, 4.79). The ^{13}C NMR spectrum exhibits five carbon signals in the aliphatic region, four *O*-methyls, one methylenedioxy, and one *N*-methyl, as well as 27 aromatic carbons, of which ten signals at δ 136.4–158.0 have been assigned to aromatic carbons linked oxygen. Signals at δ 158.0 and 140.6 are ascribed to C-1' and C-3' according to the HMQC correlation experiment. The ^1H NMR spectrum reveals an E ring that is a typical 1,2,4-substituted benzene ring, and signals at δ 5.99, 6.78, 6.76 are ascribed to H-11, H-14, and H-15, respectively, and also an F ring that is 1,4-substituted, with δ 6.67, 6.73 ascribed to H-12', 14' and H-11', 15'. Therefore, **1** should possess a C-12-C-13' linkage of a diphenyl ether; C-13 is substituted by an *O*-methyl (δ 3.87) since irradiation of δ 3.87 shows a NOE enhancement to H-14.

An extensive NOE experiment indicated that C-6 and C-7 are substituted by *O*-methyl at δ 3.49, and 3.74, and the oxygen-bridge is at C-5, since irradiation of 7-OMe (δ 3.74) shows NOE enhancements to 6-OMe (δ 3.49), and H-8 (δ 6.45), while irradiation of H-1 (δ 3.57) shows NOE enhancements to H-8, not to 6,7-OMe. Irradiation of H-4' (δ 7.45) did not enhance the *O*-methyl (δ 3.56), revealing that *O*-methyl (δ 3.56) is at either C-7' or C-8', while the methylenedioxy is at C-5', C-6'. Irradiation of H-9' (δ 4.57, 4.79) gave no NOE enhancement to OCH₃ (δ 3.56), which enables the assignment of 7'-OCH₃ and the 8'-linkage of the oxygen-bridge (figure 2). All these assignments are supported by comparison with those of thalfine [5]. The HMBC experiment (table 1) allowed assignments of all the carbons.


The absolute stereochemistry of **1** was established as *S* for C-1 by comparison of its CD spectrum with that of thalfine [5], which has an *S* configuration of C-1.

Thaliatrine (**2**) was obtained as a white amorphous solid. The HR-FABMS of **2** showed the molecular ion at m/z 666 corresponding to the formula C₃₉H₄₂O₈N₂. The very weak molecular ion peak on the EIMS revealed **2** was a dimeric alkaloid with one diphenyl ether group [4]. The absence of any other strong peaks around the base peak m/z 220 suggests that the two tetrahydroisoquinoline moieties have the same substitutions [4]. Thus, rings B and C are both substituted by a methoxy and a methylenedioxy. The many overlapped and duplicate signals on the ^1H and ^{13}C NMR spectrum also indicate that the two tetrahydroisoquinoline moieties possess same structure. By comparison of ^1H NMR spectrum of **1**, compound **2** has

Table 1. ^1H and ^{13}C NMR data for compounds **1** and **2**^a.

Position	1			2		
	δ_{C}	δ_{H}	HMBC	δ_{C}	δ_{H}	HMBC
1	63.4	3.57 m	C-4a,C-8,C-10	65.0	4.12 m	C-4a,C-8,C-10
1a	134.8			132.0		
3	51.3	2.38–3.12 m		45.0	2.95–3.20 m	
4	23.0	2.50 m		18.0	2.80 m	
4a	119.8			126.0		
5	148.7			146.0		
6	136.4			134.8		
7	151.6			142.0		
8	105.4	6.46 s	C-1,C-4a,C-6,C-7	107.0	5.70 s	C-1,C-4a,C-6,C-7
9	36.4	3.18–3.29 m	C-1a,C-1,C-11,C-15	40.0	3.05 m	C-1a,C-1,C-11,C-15
10	132.6			132.5		
11	118.9	5.99 d (2.5)	C-9,C-13,C-15	112.8	6.63 d (2.5)	C-9,C-13,C-15
12	148.7			145.0		
13	148.8			150.0		
14	110.8	6.78 d (8.2)	C-10,C-12,C-13	123.0	6.90 d (8.0)	C-10,C-12,C-13
15	123.5	6.76 dd (8.2, 2.5)	C-9,C-11,C-13	126.0	6.84 dd (8.0, 2.5)	C-9,C-11,C-13
1'	158.0			65.0	4.12 m	C-4a',C-8',C-10'
1a'	118.4			134.0		
3'	140.6	8.45 d (5.8)	C-4',C-4a'	45.0	2.95–3.20 m	
4'	111.8	7.45 d (5.8)	C-3',C-1a',C-5'	18.0	2.80 m	
4a'	118.3			123.0		
5'	137.9			146.0		
6'	142.3			134.8		
7'	139.7			142.0		
8'	137.9			106.9	5.64 s	C-1',C-4a',C-6',C-7'
9'	46.7	4.57 d (14.3) 4.79 d (14.3)	C-1a',C-1',C-11'	40.0	2.72 m	C-1a',C-1',C-11'
10'	137.1			134.5		
11'	128.9	6.73 dd (8.7, 2.5)	C-9',C-12',C-13'	130.9	6.98 d (8.0)	C-9',C-12',C-13'
12'	120.8	6.67 dd (8.7, 2.5)	C-11',C-13',C-10'	116.9	6.76 d (8.0)	C-11',C-13',C-10'
13'	154.6			157.0		
14'	120.8	6.67 dd (8.7, 2.5)		116.9	6.76 d (8.0)	
15'	128.9	6.73 dd (8.7, 2.5)		130.9	6.98 d (8.0)	
MeN-1	43.8	2.28 s	C-1,C-3	42.0	2.60 s	C-1,C-3
MeN-1'				42.0	2.60 s	
MeO-6	59.9	3.49 s	C-6			
MeO-7	56.2	3.74 s	C-7	56.2	3.61 s	C-7
MeO-7'	60.4	3.57 s	C-7'	56.2	3.58 s	C-7'
MeO-13	56.2	3.87 s	C-13	57.1	3.78 s	C-13
–OCH ₂ O -5, 6				101.6	5.93 s	C-5,C-6
–OCH ₂ O -5', 6'	102.6	6.15 s	C-5',C-6'	101.6	5.93 s	C-5',C-6'

^a δ (ppm); ^1H (500 MHz) and ^{13}C (125 MHz); CDCl_3 ; J (Hz) in parentheses.

Figure 2. Key NOE correlations for **1** and **2**.

the same substituent status as **1** in rings E and F. Furthermore, the ^1H and ^{13}C NMR spectra of **2** (table 1) exhibit two *N*-methyl groups, three methoxy groups, and two methylenedioxy groups. In the NOE experiment, irradiation of δ 5.70 created NOE enhancements to an aliphatic proton (H-1) and a methoxy group (δ 3.58), indicating that δ 5.70 is to be assigned to H-8 and *O*-methyl (δ 3.58) is at C-7 while the methylenedioxy is at C-5, C-6. The placement of *O*-methyl (δ 3.61) and another methylenedioxy on ring C were also confirmed through an NOE experiment. Irradiation of OCH_3 (δ 3.78) resulted in NOE enhancement to H-14 (δ 6.90, $J = 8.0$ Hz), revealing that OCH_3 (δ 3.78) is on C-13. All of the carbon signals were assigned according to 2D CH-correlation NMR and HMBC experiments.

The absolute configuration of **2** was established from its CD spectrum by comparison with the CD spectrum of thalastine; the two compounds had similar CD spectra, thus **2** should have the *S* configuration at C-1, as with thalastine [6].

All compounds were tested for activity against platelet aggregation induced by adenosine diphosphate (ADP) and collagen (Coll) *in vitro*. Compound **1** exhibited potential inhibition of platelet aggregation.

3. Experimental

3.1 General experimental procedures

Melting points were detected on a Fisher-Johns hot-stage apparatus and are uncorrected. Optical rotation was obtained in CHCl_3 at 20°C , using a Perkin–Elmer 341 polarimeter. CDs were taken on a JASCO polarimeter. UV spectra were recorded on a Philips Pye Unicam PU8800 spectrophotometer, while IR spectra were measured on a Perkin–Elmer 983G spectrophotometer. ^1H and ^{13}C NMR, ^1H – ^1H COSY, HMQC, HMBC, and NOESY spectra were recorded on a Bruker AM-500 spectrometer, using CDCl_3 as solvent and TMS as internal standard. MS measurements were carried out on a ZABSPEC spectrometer. Column chromatography was carried out on silica gel (120–230 mesh, Merck) Preparative TLC was accomplished on silica gel GF₂₅₄ (Merck). For column chromatography, Sephadex LH-20 (Pharmacia) was also employed. Eluates were detected on TLC using Dragendorff's reagent.

3.2 Plant material

The roots of *Thalictrum atriplex* Finet et Gagnep. were collected in August 1996 at Ma-Er-Kang County, Si-Chuan Province, People's Republic of China, and identified by Professor Wen-Cai Wang, Institute of Botany, Chinese Academy of Sciences. A voucher specimen (no. 960814) has been deposited in the herbarium of the Institute of Medicinal Plant Development, Peking Union Medical College & Chinese Academy of Medical Sciences.

3.3 Extraction and isolation

The air-dried roots of *T. atriplex* (4.0 kg) were exhaustively extracted with 95% EtOH. The EtOH was then removed under reduced pressure, and the resultant residue (900 g) was dissolved in water. After filtration, the solution was then extracted several times with light petroleum. The aqueous layer was then extracted with CHCl_3 , EtOAc and *n*-BuOH,

successively. The CHCl_3 residue (53 g) was fractionated over a silica-gel column, gradiently eluting with CHCl_3 -MeOH, to give 67 fractions (each 500 ml). Fractions 28–36, 46–57, 58–67 were then combined to give fractions A, B, C, respectively, after monitoring by TLC. Fractions A, B and C were subsequently further separated by column chromatography over silica gel, eluting EtOAc-MeOH (9:1). Fractions 9–13 of A then gave compound **1** (530 mg), fractions 36–41 of B were purified with Sepadex-LH₂₀ to yield thalifaberine [7] (50 mg). Fractions 21–32 of B and 14–20 and 23–26 of C were subjected to preparative TLC, using the solvent system light petroleum (60–90°C)- CH_3COCH_3 -MeOH- NH_4OH (6:4:0.1:1), to yield pure compound **2** (170 mg), thalistine [6,8] (150 mg), and thaliracebine [5] (100 mg), respectively.

Neothalfine (1). A white amorphous powder (CH_3OCH_3), mp 132–135°C; $[\alpha]_{\text{D}} + 36.4$ (*c* 0.5, CHCl_3); CD (*c* 8.25×10^{-4} M, MeOH): $\Delta\epsilon$ (λ nm) -5.1346 (289), $+9.2962$ (264), $+10.3812$ (235), $+2.1634$ (221), $+20.5107$ (210); UV λ_{max} (MeOH) (nm): 210, 240 (sh), 256, 340; IR (KBr) ν_{max} (cm^{-1}): 2960, 1610, 1520, 1460, 1420, 1350, 1280, 1240, 1180, 1140, 1120, 1090, 1065, 1045, 980; ^1H and ^{13}C NMR, see table 1; EIMS *m/z* [M]⁺ 648 (100), 633 (97), 422 (10), 324 (99), 220 (60), 205 (80), 190 (70), 174 (35); HR-FABMS *m/z* 648.2479 (calcd. for $\text{C}_{38}\text{H}_{36}\text{O}_8\text{N}_2$ 648.2471).

Thaliatrine (2). A white amorphous powder (CH_3OCH_3), mp 89–90°C; $[\alpha]_{\text{D}} + 42.2$ (*c* 0.9, CHCl_3); CD (*c* 8.25×10^{-4} M, MeOH): $\Delta\epsilon$ (λ nm) -0.6783 (299), $+0.5723$ (286), $+14.14$ (227); UV λ_{max} (MeOH) (nm): 210, 274; IR (KBr) ν_{max} (cm^{-1}): 2960, 1650, 1610, 1516, 1460, 1380, 1280, 1230, 1140, 1065, 960; ^1H and ^{13}C NMR, see table 1; EIMS *m/z* [M]⁺ 666 (5), 445 (75), 430 (95), 220 (100), 205 (10), 190 (15), 174 (8), 147 (12); HR-FABMS *m/z* 666.3048 (calcd. for $\text{C}_{39}\text{H}_{42}\text{O}_8\text{N}_2$ 666.3041).

Acknowledgements

The authors are grateful to the National Natural Science Foundation of the People's Republic of China for financial support. We thank Professor Wen-Cai Wang for the species identification, and Professor Nan-Nan Gao, Institute of Medicinal Plant Development, Peking Union Medical College & Chinese Academy of Medical Sciences, for assistance with the antiplatelet activity assay.

References

- [1] G.Y. Gao, P.G. Xiao. *Nat. Prod. Res. Dev.*, **11**, 96 (1999).
- [2] G.Y. Gao, J.S. Yang, P.G. Xiao. *World Notes Plant Med.*, **15**, 14 (2000).
- [3] Z.Y. Wu, T.Y. Zhou, P.G. Xiao. *Xin Hua Compendium of Materia Medica*, p. 134, vol. 1, Shanghai Science & Technology Press, Shanghai (1998).
- [4] P.Z. Cong. *Application of Mass Spectrometry in Natural Organic Chemistry*, p. 274, Science Press, Beijing (1987).
- [5] W.T. Liao, J.L. Beal, W.N. Wu, R.W. Dorskotch. *Lloydia*, **41**, 257 (1978).
- [6] W.N. Wu, W.T. Liao, Z.F. Mahmoud. *J. Nat. Prod.*, **43**, 472 (1980).
- [7] L.Z. Lin, S.F. Hu, K. Zaw, C.K. Angerhofer, H. Chai, J.M. Pezzuto, G.A. Cordell, J. Lin, D.M. Zheng. *J. Nat. Prod.*, **57**, 1430 (1994).
- [8] L. Paul, J.R. Schiff. *J. Nat. Prod.*, **54**, 645 (1991).